Volume 56, Pages S213-S215 (July 1999) Erythropoietin supplement increases plasma lipoprotein lipase and hepatic triglyceride lipase levels in hemodialysis patients  Tetsuya Goto, M.D., Hiroko Saika, Toshio Takahashi, Akefumi Maeda, Masatoshi Mune, Susumu Yukawa  Kidney International  Volume 56, Pages S213-S215 (July 1999) DOI: 10.1046/j.1523-1755.1999.07155.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Changes in plasma lipoprotein lipase (LPL) levels prior to and one month after the start of the erythropoietin (EPO) supplement therapy in hemodialysis (HD) patients. (A) HD patients at the initial stage (N = 12). (B) HD patients at the maintenance stage (N = 8). *P < 0.05 vs. plasma LPL levels prior to the start of the EPO supplement therapy in HD patients. Also, mean values and SD are given. Kidney International 1999 56, S213-S215DOI: (10.1046/j.1523-1755.1999.07155.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Changes in plasma hepatic triglyceride lipase (HTGL) levels prior to and one month after the start of the erythropoietin (EPO) supplement therapy in hemodialysis (HD) patients. (A) HD patients at the initial stage (N = 12). (B) HD patients at the maintenance stage (N = 8). *P < 0.05 vs. plasma HTGL levels prior to the start of the EPO supplement therapy in HD patients. Also, mean values and SD are given. Kidney International 1999 56, S213-S215DOI: (10.1046/j.1523-1755.1999.07155.x) Copyright © 1999 International Society of Nephrology Terms and Conditions